Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
Open accessAbstract
As dyslipidemias remain one of the main risk factors for developing cardiovascular disease, the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of interest worldwide. In contrast to conventional pharmacotherapy, human monoclonal antibodies directed against proprotein convertase subtilisin/kexin type 9 (PSCK9) and small interfering RNA- (siRNA-) based drug targeting PCSK9 represent a new strategy for managing lipid disorders and reducing cardiovascular risk. Inclisiran is a long-acting, synthetic siRNA that targets hepatic production of PCSK9 and consequently causes a reduction in LDL-C concentrations by approximately 50% compared to placebo. The structural modification of inclisiran has led to better stability and prolonged biological activity of the drug. The main advantage over conventional pharmacotherapy and anti-PCSK9 monoclonal antibodies is its favorable administration regimen (0-90-180 days), which should lead to much better compliance. Clinical trials conducted so far have confirmed the tolerability and efficacy of inclisiran in long-term PCSK9 and LDL-C level reductions. Moreover, a short-term follow-up on the safety of inclisiran showed a relatively good safety profile of the drug. However, it is still of great importance for ongoing and forthcoming clinical trials to be continued on a larger group of patients in order to assess long-term tolerability, efficacy, and safety of inclisiran.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The therapeutic mechanism of inclisiran differs from monoclonal antibodies because inclisiran operates inside cells instead of binding PCSK9 molecules outside cells.
“The therapeutic mechanism of Inclisiran differs from monoclonal antibodies because Inclisiran operates inside cells instead of binding PCSK9 molecules outside cells [14, 66].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961 · see citing works
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854 · see citing works
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665 · see citing works
Cardiovascular Diseases (CVDs)
de la Zerda, A., & Wang, S. X. (2022) · doi:10.1002/9781118910573.ch5 · Cited by 1,281 · see citing works
Anderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J., Grover, S., Gupta, M., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.510 · Cited by 1,173 · see citing works
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992 · see citing works
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818 · see citing works
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768 · see citing works
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., II, Goldstein, L. B., Chin, C. C., Tannock, L. R., Miller, M. J., Raghuveer, G., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 761 · see citing works
Frank-Kamenetsky, M. D., Grefhorst, A., Anderson, N. N., Racie, T., Bramlage, B., Akinc, A., Butler, D., Charissé, K., Dorkin, J. R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 635 · see citing works
Fitzgerald, K. J., Frank-Kamenetsky, M. D., Shulga‐Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J. E., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 574 · see citing works
Backer, G. D., Jankowski, P., Kotseva, K., Mirrakhimov, E. M., Reiner, Ž., Rydén, L., Tokgözoğlu, L. S., Wood, D., Bacquer, D. D., Backer, G. D., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.03.014 · Cited by 391 · see citing works
Self-citationLamb, Y. N. (2021) · Drugs · doi:10.1007/s40265-021-01473-6 · Cited by 375 · see citing works
Reiner, Ž., Backer, G. D., Fras, Z., Kotseva, K., Tokgözoğlu, L. S., Wood, D., & Bacquer, D. D. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.018 · Cited by 210 · see citing works
Self-citationOligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs
Khvorova, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1614154 · Cited by 184 · see citing works
Wright, R. S., Collins, M. G., Stoekenbroek, R. M., Robson, R. A., Wijngaard, P. L. J., Landmesser, U., Leiter, L. A., Kastelein, J. J. P., Ray, K. K., & Kallend, D. G. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.08.021 · Cited by 158 · see citing works
Ray, K. K., Stoekenbroek, R. M., Kallend, D., Leiter, L. A., Landmesser, U., Wright, R. S., Wijngaard, P., & Kastelein, J. J. P. (2018) · Circulation · doi:10.1161/circulationaha.118.034710 · Cited by 154 · see citing works
Adverse Effects of Statins - Myths and Reality
Simic, I., & Reiner, Z. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612820666141013134447 · Cited by 126 · cited 1× · see citing works
“Moreover, chronic statin therapy is associated with adverse effects, such as myalgia and myopathies, and its occurrence is one of the major reasons for discontinuation of the therapy [8, 9].”
BackgroundSelf-citationInclisiran—New hope in the management of lipid disorders?
Dyrbuś, K., Gąsior, M., Penson, P., Ray, K. K., & Banach, M. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.11.001 · Cited by 120 · see citing works
Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients
Gitt, A. K., Lautsch, D., Ferrières, J., Kastelein, J. J. P., Drexel, H., Horack, M., Brudi, P., Vanneste, B., Bramlage, P., Chazelle, F., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.09.004 · Cited by 115 · see citing works
Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators
Flierl, U., Nero, T. L., Lim, B., Arthur, J. F., Yao, Y., Jung, S. M., Gitz, E., Pollitt, A. Y., Zaldivia, M. T. K., Jandrot-Perrus, M., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140391 · Cited by 114 · see citing works
Banach, M., Penson, P. E., Vrablı́k, M., Bunc, M., Dyrbuś, K., Fedačko, J., Gaiță, D. I., Gierlotka, M. J., Járai, Z., Magda, S. L., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105499 · Cited by 102 · see citing works
Self-citationInclisiran: a new promising agent in the management of hypercholesterolemia
Kosmas, C. E., Muñoz Estrella, A., Sourlas, A., Silverio, D., Hilario, E., Montan, P. D., & Guzman, E. (2018) · Diseases · doi:10.3390/diseases6030063 · Cited by 99 · see citing works
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia
Khan, S. A., Naz, A., Qamar Masood, M., & Shah, R. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.08.018 · Cited by 98 · see citing works
Landmesser, U., Haghikia, A., Leiter, L. A., Wright, R. S., Kallend, D., Wijngaard, P., Stoekenbroek, R., Kastelein, J. J., & Ray, K. K. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa077 · Cited by 83 · see citing works
Seidah, N. G. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100130 · Cited by 75 · see citing works
Inclisiran for the treatment of dyslipidemia
Nishikido, T., & Ray, K. K. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1442435 · Cited by 56 · see citing works
Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis
Vena, G. A., Cassano, N., & Iannone, F. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s154745 · Cited by 50 · see citing works
PCSK9 inhibitors in clinical practice: Expectations and reality
Reiner, Ž. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.01.001 · Cited by 36 · see citing works
Self-citationNovel Experimental Agents for the Treatment of Hypercholesterolemia
Pećin, I., & Reiner, Ž. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267376 · Cited by 19 · see citing works
Self-citationBrandts, J., & Ray, K. K. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000691 · Cited by 15 · see citing works
Lamb, Y. N. (2021) · Figshare · doi:10.6084/m9.figshare.13550015 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Low-density lipoprotein particles in atherosclerosis
Qiao, Y.-N., Zou, Y., & Guo, S. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.931931 · Cited by 114 · see citing works
A Comprehensive Review of PCSK9 Inhibitors
Coppinger, C., Movahed, M. R., Azemawah, V., Peyton, L., Gregory, J., & Hashemzadeh, M. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221100107 · Cited by 99 · see citing works
Lipid Lowering Therapy: An Era Beyond Statins
Abdul‐Rahman, T., Bukhari, S. M. A., Cantu‐Herrera, E., Awuah, W. A., Lawrence, J. A., de Andrade, H., Patel, N., Shah, R. M., Shaikh, R., Capriles, C. A. A., et al. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101342 · Cited by 91 · see citing works
Targeted Strategy in Lipid-Lowering Therapy
Dayar, E., & Pecháňová, O. (2022) · Biomedicines · doi:10.3390/biomedicines10051090 · Cited by 59 · see citing works
Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
Gareri, C., Polimeni, A., Giordano, S. A., Tammè, L., Curcio, A., & Indolfi, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133884 · Cited by 59 · see citing works
Inclisiran: a new generation of lipid-lowering siRNA therapeutic
Zhang, Y., Chen, H., Hong, L., Wang, H., Li, B., Zhang, M., Li, J., Liu, Y., & Liu, F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1260921 · Cited by 59 · see citing works
Inclisiran: A Review in Hypercholesterolemia
Frampton, J. E. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00568-7 · Cited by 55 · see citing works
Current Understanding on the Role of Lipids in Macrophages and Associated Diseases
Florance, I., & Seenivasan, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010589 · Cited by 50 · see citing works
Bosco, G., Di Giacomo Barbagallo, F., Spampinato, S., Lanzafame, L., Di Pino, A., Piro, S., Purrello, F., & Scicali, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062444 · Cited by 50 · see citing works
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Wołowiec, Ł., Osiak, J., Wołowiec, A., Wijata, A., Grześk, E., Kozakiewicz, M., Banach, J., Nowaczyk, A., Nowaczyk, J., & Grześk, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020323 · Cited by 43 · see citing works
Gunta, S. P., O’Keefe, J. H., O’Keefe, E. L., & Lavie, C. J. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.02.007 · Cited by 42 · see citing works
Thau, H., Neuber, S., Emmert, M. Y., & Nazari‐Shafti, T. Z. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00353-w · Cited by 39 · see citing works
New Therapeutic Approaches in Treatment of Dyslipidaemia—A Narrative Review
Merćep, I., Strikić, D., Slišković, A. M., & Reiner, Ž. (2022) · Pharmaceuticals · doi:10.3390/ph15070839 · Cited by 37 · see citing works
Self-citationBosco, G., Barbagallo, F. D. G., Marco, M. D., Scilletta, S., Miano, N., Esposto, S., Pennisi, G., Prezzavento, S., Gallo, A., Francesco, E. M. D., et al. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.05.008 · Cited by 34 · see citing works
PCSK9 inhibition: from effectiveness to cost-effectiveness
Mercep, I., Strikic, D., Hrabac, P., Pecin, I., & Reiner, Ž. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1339487 · Cited by 31 · see citing works
Self-citationHuo, Y., Chen, B., Lian, Q., Wang, S., Liu, L., Lu, D., Qu, Y., Zheng, G., Li, L., Ji, Y., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100907 · Cited by 28 · see citing works
The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies
Chan, D. C., & Watts, G. F. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.07.008 · Cited by 27 · see citing works
Zhang, S., Sun, L., Xu, X., Zhang, Y., & Chen, Q. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04321-z · Cited by 22 · see citing works
Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy
Dec, A., Niemiec, A., Wojciechowska, E., Maligłówka, M., Bułdak, Ł., Bołdys, A., & Okopień, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076858 · Cited by 22 · see citing works
Current usage of inclisiran for cardiovascular diseases: overview of current clinical trials
Harbi, M. H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1449712 · Cited by 20 · see citing works
Present and Future of Dyslipidaemia Treatment—A Review
Merćep, I., Vujević, A., Strikić, D., Radman, I. B., Pećin, I., & Reiner, Ž. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185839 · Cited by 20 · see citing works
Self-citationBasiak, M., Hachuła, M., Kosowski, M., Machnik, G., Maligłówka, M., Dziubinska-Basiak, M., Krysiak, R. G., & Okopień, B. (2023) · Molecules · doi:10.3390/molecules28155928 · Cited by 15 · see citing works
Appropriateness of Dyslipidemia Management Strategies in Post-Acute Coronary Syndrome: A 2023 Update
Lucà, F., Oliva, F. G., Rao, C. M., Abrignani, M. G., Amico, A. F., Fusco, S. A. D., Caretta, G., Matteo, I. D., Nora, C. D., Pilleri, A., et al. (2023) · Metabolites · doi:10.3390/metabo13080916 · Cited by 16 · see citing works
Zhou, W., Liang, Z., Lou, X., Wang, N., Liu, X., Li, R., & Pai, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1283922 · Cited by 14 · see citing works
Berberine: Ins and outs of a nature-made PCSK9 inhibitor
Ataei, S., Kesharwani, P., & Sahebkar, A. (2022) · EXCLI journal · doi:10.17179/excli2022-5234 · Cited by 14 · see citing works
Familial Hypercholesterolaemia as a Predisposing Factor for Atherosclerosis
Poznyak, A. V., Litvinova, L. S., Poggio, P., Orekhov, A. N., & Melnichenko, A. А. (2022) · Biomedicines · doi:10.3390/biomedicines10102639 · Cited by 13 · see citing works
Iqbal, S., Sabbour, H. M., Ashraf, T., Santos, R. D., & Buckley, A. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.12.003 · Cited by 13 · see citing works
Advances in Oral Biomacromolecule Therapies for Metabolic Diseases
Jiao, Q., Huang, Y., He, J., & Xu, Y. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020238 · Cited by 12 · see citing works
Dutta, S., Shah, R., Singhal, S., Singh, S., Piparva, K. G., & Katoch, C. D. S. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2293201 · Cited by 12 · see citing works
Atherosclerotic cardiovascular disease landscape in Singapore
Sia, C., Simon, O., Loh, P. H., & Poh, K. K. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1342698 · Cited by 12 · see citing works
Mansoor, T., Rao, B. H., Gupta, K., Parikh, S. S., Abramov, D., Mehta, A., Al Rifai, M., Virani, S. S., Nambi, V., Minhas, A. M. K., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00712-x · Cited by 12 · see citing works
Li, J., Lei, X., Li, Z., & Yang, X. (2023) · Medicine · doi:10.1097/md.0000000000032728 · Cited by 12 · see citing works
Zyryanov, S. K., & Butranova, O. I. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-5271 · Cited by 10 · see citing works
Basit, J., Ahmed, M., Singh, P., Ahsan, A., Zulfiqar, E., Iqbal, J., Fatima, M., Upreti, P., Hamza, M., & Alraies, M. C. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70039 · Cited by 10 · see citing works
Reshaping Dyslipidaemia Treatment with Bempedoic Acid—A Narrative Review
Strikić, D., Begic, Z., Radman, I. B., Zlopasa, F., Mateljic, J., Zec, I., Titlić, M., Slišković, A. M., Pećin, I., Reiner, Ž., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13061460 · Cited by 10 · see citing works
Self-citationLucà, F., Pavan, D., Gulizia, M. M., Manes, M. T., Abrignani, M. G., Benedetto, F. A., Bisceglia, I., Brigido, S., Caldarola, P., Calvanese, R., et al. (2024) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae034 · Cited by 10 · see citing works
Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis
Poznyak, A. V., Sukhorukov, V. N., Eremin, I. I., Nadelyaeva, I. I., Gutyrchik, N. A., & Orekhov, A. N. (2023) · Biomedicines · doi:10.3390/biomedicines11020503 · Cited by 8 · see citing works
From clinical development to real-world outcomes with inclisiran
Connolly, D. L., Sharma, V., & Ray, K. K. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000954 · Cited by 7 · see citing works
EZH2 as a potential therapeutic target for gastrointestinal cancers
Hashemi, M., Nazdari, N., Abad, G. G. Y., Paskeh, M. D. A., Jafari, A. M., Nemati, F., Khodaei, E., Abyari, G., behdadfar, N., Raei, B., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154988 · Cited by 7 · see citing works
Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies
Omari, M., & Alkhalil, M. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040126 · Cited by 8 · see citing works
Designing nucleic acid-based therapeutics for cancer treatment: Updates on the state of the art
Peng, B., Jayasinghe, M. K., Le, A. H., Tran, N. M., & Le, M. T. N. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.041 · Cited by 6 · see citing works
Effects of Inclisiran, Alirocumab, Evolocumab, and Evinacumab on Lipids: A Network Meta-Analysis
Zhang, L., Li, B., Chen, W., Li, W., Yang, H., & Pan, D. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25248 · Cited by 6 · see citing works
Trends in Lipid‐Lowering Agent Consumption in Croatia: A 25‐Year Observational Study
Belančić, A., Štiglić, M. K., Prgomet, L., Pećin, I., Reiner, Ž., & Vitezić, D. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70122 · Cited by 6 · see citing works
Self-citationMorales, C., Arias‐Carrasco, R., Maracaja‐Coutinho, V., Pamela Serón, S., Lanas, F. T., Salazar, L. A., & Saavedra, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087213 · Cited by 6 · see citing works
He, Y., Guan, X., Zhang, Y., Zhu, Z., Zhang, Y., Feng, Y., & Li, X. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2348562 · Cited by 6 · see citing works
Satyam, S. M., El-Tanani, M., Patni, M. A., Rehman, A., Irshad, S. M., Raheem, R., Junais, E., John, A. A., Rassal, R. Y., Kumari, R., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05515-3 · Cited by 5 · see citing works
RNA-based drugs: current, imminent and possible therapeutic applications
Torrisi, S. A., Geraci, F., Diolosà, L., Luca, A. D., Falzone, L., Drago, F., Libra, M., & Leggio, G. M. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108958 · Cited by 7 · see citing works
Pang, J., Sanfilippo, F. M., Chan, D. C., & Watts, G. F. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000842 · Cited by 5 · see citing works
Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia
ALGhasab, N. S., Fogacci, F., Арманович, А. А., & Cicero, A. F. G. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2406270 · Cited by 5 · see citing works
Ballantyne, C. M., Graham, T. E., Anglen, L. J. V., Iteld, B. J., Serota, H., Niu, X., McElligott, S. C., Hanna, K. E., & Varisco, T. J. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00438-0 · Cited by 4 · see citing works
Emerging therapies for refractory hypercholesterolemia: a narrative review
Pawlos, A., Khoury, É., & Gaudet, D. (2024) · Future Cardiology · doi:10.1080/14796678.2024.2367860 · Cited by 4 · see citing works
Tsamoulis, D., Rallidis, L. S., & Kosmas, C. E. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2360415 · Cited by 4 · see citing works
Kubo, T., Yanagihara, K., Nishimura, Y., Iino, Y., Komatsu, T., Tansou, R., Mihara, K., & Seyama, T. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00502 · Cited by 4 · see citing works
Unraveling the Link Between Aortic Stenosis and Atherosclerosis: What Have We Learned?
Cinezan, C., Rus, C. B., & Ilias, I. T. (2025) · Medicina · doi:10.3390/medicina61081375 · Cited by 4 · see citing works
George, M., Maurina, I., & Schutte, A. E. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03413-2 · Cited by 3 · see citing works
A Systematic Review of the Randomized Controlled Trials of Gemcabene and Its Therapeutic Uses
Besekar, S., Jogdand, S., & Naqvi, W. M. (2023) · Cureus · doi:10.7759/cureus.36811 · Cited by 3 · see citing works
PCSK9 siRNA INHIBITOR INCLISIRAN AS A TREATMENT OPTION IN HYPERCHOLESTEROLEMIA: A BRIEF REVIEW
Kılıç, M. E. (2023) · TURKISH MEDICAL STUDENT JOURNAL · doi:10.4274/tmsj.galenos.2023.2023-5-1 · Cited by 3 · see citing works
Identification of benzothiazoles as novel PCSK9 inhibitors
Ma, Z., Liu, H., Jiang, S., Li, W., Li, Y., Liu, Y., Wang, L., & Li, W. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129542 · Cited by 3 · see citing works
Li, W., Sun, L., & Yan, S. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1375040 · Cited by 3 · see citing works
Li, F., Ye, H., Chen, L., Ma, Y., & Chen, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1554631 · Cited by 2 · see citing works
Xiao, Q., Wang, M., Wang, S., Wang, L., & Ding, H. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07647-0 · Cited by 2 · see citing works
Non-coding RNA and Atherosclerosis
Adyan, A., Bezsonov, E. E., Grebenshchikov, E. S., Гринев, А. В., & Bogomolov, D. (2024) · Gene Expression · doi:10.14218/ge.2023.00117 · Cited by 1 · see citing works
Brennan, P. G., Mota, L., Aridi, T. G., Patel, N., Liang, P., & Ferran, C. J. (2024) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2024.01.031 · Cited by 2 · see citing works
Jallorina, A. G., Vij, K., Wan, L., Thomas, J., Drum, D., Glick, S. A., & Lee-Wong, M. F. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001660 · Cited by 2 · see citing works
Basak, A. (2025) · Biomolecules · doi:10.3390/biom15040468 · Cited by 3 · see citing works
Zhao, J., Tong, X., Peng, J., Lyu, C., & Lu, S. T. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2503094 · Cited by 1 · see citing works
LIpid Response to Statins ± Ezetimibe In Mumbai (LIRIM): A Cross-sectional Observational Study
Shah, V. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0622 · Cited by 1 · see citing works
Recent Insights into Nano-mediated siRNA Drug Delivery
Krishnaswami, V., Janakiraman, K., Sethuraman, V., Raja, J., Muruganantham, S., & Chelladurai, S. (2024) · Current Drug Metabolism · doi:10.2174/0113892002339055241211050131 · Cited by 1 · see citing works
First case report of inclisiran therapy in a heart transplant patient
Solano, A., FILIPPO, O. D., Raineri, C., D’ASCENZO, F., & Ferrari, G. M. D. (2025) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.25.06968-6 · Cited by 1 · see citing works
siRNA: A Comprehensive Review of Marketed Products till August 2022
Ghosh, R., Nayan, M. I. H., & Nandi, T. (2023) · Journal of Advances in Medical and Pharmaceutical Sciences · doi:10.9734/jamps/2023/v25i1596 · Cited by 1 · see citing works
Jawwad, M., Riaz, M., Mehtab, M., Chaudhary, M. Y. N., Kumari, J., Ahmad, W., Aslam, H., Masood, F., Rehman, W. U., Rahman, I., et al. (2023) · Critical Pathways in Cardiology A Journal of Evidence-Based Medicine · doi:10.1097/hpc.0000000000000340 · Cited by 1 · see citing works
Li, Y., Xue, K., Hu, R., Hu, X., Guo, R., Hongxia, G., & Li, G. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00702-z · Cited by 3 · see citing works
Su, Z., Liao, Z., Chen, X., Tang, J., & Wang, Y. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2438753 · Cited by 2 · see citing works
Inclisiran - hope in the fight against dyslipidemia
KRAWIEC, P., MADEJ, K., WOLANIN, I., ZIELONKA, B., KOWALCZYK, I., STACHYRA, B., WOLANIN, M., STAWIKOWSKI, C., Dengler, B., & Osińska, A. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.27.01.001 · Cited by 1 · see citing works
Tran, T. T. M., Tran, B. T., Nguyen, M. T., Hong, D. D. T., Nguyen, V. T., Nguyen, N. B. K., Pham, T. T. H., Ho, U. P., Vo, H. L., Luong, T. T. T., et al. (2023) · Tạp chí Y Dược Huế · doi:10.34071/jmp.2023.6.1
Focused Cardiovascular Risk Assessment and Approaches in Men
Cheung, B., Faruque, S. C., Kim, K., Lam, S., Faaborg-Andersen, C. C., McLaughlin, T. J., Sperling, L. S., & Eapen, D. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_19
Recent Advances in Medications for Reducing Lipid Levels
Hu, X., Jia, X. T., & Wang, X. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001020
Liu, D., Liu, J., Mao, W., Li, X., Hu, B., Zhang, L., & Hu, J. Y. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001778
Evidence‐Based Recommendations on the Use of Inclisiran in Patients With Chronic Kidney Disease
Sharma, S., Kalra, S., Sahay, M., Kapoor, N., Nagendra, L., Verma, H., Sharma, N., Verma, M., RAJU, D. S. B., & Tang, S. C. W. (2026) · Nephrology · doi:10.1111/nep.70206
Parameswaran, T., Hooper, A. J., & Burnett, J. R. (2026) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2026.2662915
Ariyanti, D., Rayyan, M. I. R., Shabri, H. A., Nurwahyudi, N., Husniatama, M. D., Erisadana, R. N., Larasati, S., Mustofa, A., Faizah, N. N., Putranto, J. N. E., et al. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2662127
The secretory PCSK family in cardiovascular disease and beyond
Seidah, N. G. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120716
Single-Cell Analysis in Pharmacological Research for Blood Lipid Disorders
Dang, H.-L., Hoang, D.-A., & Chu, D.-T. (2026) · Springer eBooks · doi:10.1007/978-981-95-9789-5_16
Apolipoprotein E Mimetic Peptide-Mediated Modulation of Lipid Homeostasis
Patel, D. R., Martin, C. L., Anantharamaiah, G. M., & Aller, S. G. (2026) · Biomolecules · doi:10.3390/biom16091352
Zhu, P., Huang, Y., Pan, L., Leng, Y., Zheng, H., Zhou, Y., Shi, W., Zhang, D., & Li, Y. (2026) · Nano Letters · doi:10.1021/acs.nanolett.6c03833
Rehman, M. A., Oduoye, M. O., Ozoemena, D. J., Danso, E. A., Chukwuka, G., & Odelade, M. A. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1911458
- Authors
- Merćep, I., Friščić, N., Strikić, D., & Reiner, Ž.
- Affiliations
- University Hospital Centre Zagreb (HR)
- Corresponding author
- Merćep, Iveta
- Venue
- Cardiovascular Therapeutics
- Publisher
- Wiley
- Published
- 2022-02-10
- Volume
- 2022
- Pages
- 1-6
- ISSN
- 1755-5914 (ISSN-L)
- 1755-5922
- PMC
- PMC8853778
- OpenAlex
- W4211127626
- Cited by
- 85
- References
- 32
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 25 · 2023: 24 · 2022: 10
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Cardiovascular Therapeutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Keywords
- inclisiran, PCSK9, siRNA, LDL cholesterol lowering, dyslipidemia, cardiovascular risk, anti-PCSK9 monoclonal antibodies, safety and tolerability
- MeSH terms
- Proprotein Convertase 9, Anticholesteremic Agents, Humans, Cholesterol, LDL, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
